The impact of adenosine kinase inhibition on development of epilepsy


  • Transient administration of the adenosine kinase (ADK)‐inhibitor 5‐iodotubercidin (5-ITU) during the latent period of epileptogenesis has a robust and lasting antiepileptogenic effect in a murine model of temporal lobe epilepsy (TLE).

Why this matters

    Over one‐third of people with epilepsy are refractory to treatment and there is a need for new drugs that can prevent disease development and progression; novel small‐molecule ADK inhibitors offer promise as future antiepileptogenic drugs.